SAN DIEGO, January 10, 2017 /PRNewswire/ --
Entest BioMedical Inc. (OTCPINK: ENTB) announced today that its wholly owned subsidiary, Zander Therapeutics, Inc., has filed of a United States patent application covering use of newly identified activators of NR2F6 for the treatment of a Racehorse-specific condition termed "Exercise Induced Pulmonary Hemorrhage (EIPH)." This condition is characterized by the presence of blood in the airways of a horse's lung during exercise. According to a recent study, 60 percent of Thoroughbred racehorses have evidence of blood in their trachea, with 20 percent having moderate to severe EIPH (grades 2-4) after any given race. Horses with a grade 2 score or higher have significantly decreased performance.
Recent studies have shown that EIPH is associated with production of inflammatory cytokines in the lung of the horse subsequent to repeated stress associated with hyper-performance. These cytokines, such as TNF-alpha, have previously been shown to be inhibited by augmentation of NR2F6.
"According to the American Horse Council, the horse industry contributes approximately $39 billion to the American Economy," said David Koos, Chairman and CEO of Zander Therapeutics. "We believe that by addressing one of the major concerns associated with horse racing, we not only provide a solution to a major unmet need, but also develop a business case for the value of applying discoveries made in human medicine to the veterinary space."
"Currently the only treatment for EIPH is administration of the diuretic drug Lasix, this practice does not address the underlying problem, which is the inflammatory cascade, and may have long term detriments to the equine patient," said Thomas Ichim, PhD, consultant to Zander and co-inventor of the patent application. "It is very exciting for me to see potential veterinary applications of the findings of the NR2F6 research conducted by Regen BioPharma (OTCQB: RGBP) which has licensed these veterinary applications of their technology to Zander Therapeutics Inc. The number of drug developers is substantially smaller in veterinary medicine than in human medicine which could eventually lead to a strong presence in this market place for Zander."
Zander Therapeutics Inc. is the exclusive licensee for veterinary applications of Regen BioPharma Inc. (OTCQB: RGBP) (OTCQB: RGBPP) intellectual property and technology relating to NR2F6. NR2F6 is a molecular switch known as a "orphan nuclear receptor", which controls genes associated with the immune response. Zander Therapeutics is solely focused on veterinary applications.
David Koos serves as Chairman and Chief Executive officer of Regen BioPharma, Inc. (OTCQB: RGBP), Entest BioMedical Inc. (OTCPINK: ENTB) and Zander Therapeutics Inc. (wholly owned by Entest BioMedical Inc.).
About Zander Therapeutics Inc.:
Zander Therapeutics is a wholly owned subsidiary of Entest BioMedical Inc. (OTCPink: ENTB), a publicly traded biotechnology company focused on veterinary medicine. The Company seeks to develop small molecule and immune stimulating therapies for veterinary application. Currently, the Company's major interest is in developing small molecule therapies for treating cancer and autoimmune diseases in animals.
Disclaimer: This news announcement may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
 Morley et al. et al. Exercise-induced pulmonary haemorrhage impairs racing performance in Thoroughbred racehorses. Equine Vet J 2015; 47:358-365
Zander Therapeutics Inc. and Entest BioMedical Inc.
David R. Koos, Ph.D.
Chairman & Chief Executive Officer
SOURCE Entest BioMedical Inc.